CYCLO THERAPEUTICS INC (CYTH) Stock Price & Overview
NASDAQ:CYTH • US23254X2018
The current stock price of CYTH is 0.7206 USD. Today CYTH is up by 1.39%. In the past month the price decreased by -5.31%. In the past year, price decreased by -48.16%.
CYTH Key Statistics
- Market Cap
- 23.722M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.92
- Dividend Yield
- N/A
CYTH Stock Performance
CYTH Stock Chart
CYTH Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CYTH. When comparing the yearly performance of all stocks, CYTH is a bad performer in the overall market: 63.48% of all stocks are doing better.
CYTH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CYTH. CYTH may be in some trouble as it scores bad on both profitability and health.
CYTH Earnings
On March 25, 2025 CYTH reported an EPS of -0.27 and a revenue of 233.00K. The company missed EPS expectations (-68.96% surprise) and missed revenue expectations (-22.3% surprise).
CYTH Forecast & Estimates
9 analysts have analysed CYTH and the average price target is 0.97 USD. This implies a price increase of 34.47% is expected in the next year compared to the current price of 0.7206.
For the next year, analysts expect an EPS growth of 56.84% and a revenue growth -41.47% for CYTH
CYTH Groups
Sector & Classification
CYTH Financial Highlights
Over the last trailing twelve months CYTH reported a non-GAAP Earnings per Share(EPS) of -0.92. The EPS increased by 44.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -472.02% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CYTH Ownership
CYTH Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.85 | 410.651B | ||
| AMGN | AMGEN INC | 16.4 | 197.945B | ||
| GILD | GILEAD SCIENCES INC | 16.14 | 180.072B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 116.919B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.36 | 80.868B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.87 | 42.343B | ||
| INSM | INSMED INC | N/A | 30.619B | ||
| NTRA | NATERA INC | N/A | 27.941B | ||
| BIIB | BIOGEN INC | 12.15 | 27.603B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.01 | 21.26B | ||
| MRNA | MODERNA INC | N/A | 21.03B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.746B | ||
| EXAS | EXACT SCIENCES CORP | 309.36 | 19.715B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CYTH
Company Profile
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. The company is headquartered in Gainesville Florida, Florida and currently employs 8 full-time employees. The company went IPO on 2004-02-27. The Company’s Trappsol Cyclo, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C1, a rare and fatal genetic disease, (NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The firm is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842).
Company Info
CYCLO THERAPEUTICS INC
6714 Nw 16Th Street, Suite B
Gainesville Florida FLORIDA 32653 US
CEO: N. Scott Fine
Employees: 8
Phone: 13864188060
CYCLO THERAPEUTICS INC / CYTH FAQ
What does CYCLO THERAPEUTICS INC do?
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. The company is headquartered in Gainesville Florida, Florida and currently employs 8 full-time employees. The company went IPO on 2004-02-27. The Company’s Trappsol Cyclo, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C1, a rare and fatal genetic disease, (NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The firm is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842).
What is the current price of CYTH stock?
The current stock price of CYTH is 0.7206 USD. The price increased by 1.39% in the last trading session.
Does CYCLO THERAPEUTICS INC pay dividends?
CYTH does not pay a dividend.
What is the ChartMill rating of CYCLO THERAPEUTICS INC stock?
CYTH has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of CYTH stock?
CYCLO THERAPEUTICS INC (CYTH) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for CYCLO THERAPEUTICS INC?
CYCLO THERAPEUTICS INC (CYTH) has a market capitalization of 23.72M USD. This makes CYTH a Nano Cap stock.